Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ALAlumis Inc. logo

Alumis Inc. (ALMS)

NASDAQ · Currency in USD
$6.78 ▼ -0.04 (-0.59%)
At close: Oct 23, 4:00 PM ET. Market closed.
$6.78 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$6.82
Open
$6.68
Day's Range
$6.48 – $6.83
52 Week Range
$4.39 – $31.35
Volume
1,230,171
Avg. Volume
2,290,929
Market Cap
$877.57M
Beta (5Y Monthly)
-0.67
PE Ratio (TTM)
--
EPS (TTM)
-$3.44
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$29.57

Profile: Alumis Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
237
CEO
Martin Babler
Website
alumis.com

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.73 · Revenue est. $1.90M
DateEst.Actual
Aug 13, 2026-$0.77-$1.11Miss
May 14, 2026-$0.74-$0.74Beat
Mar 19, 2026-$0.97-$0.95Beat
Nov 13, 2025-$0.92-$1.06Miss
Aug 13, 2025-$1.11-$1.17Miss
May 14, 2025-$1.47-$1.82Miss

Analyst view

Consensus price target
$29.57 ▲ +336.1%
Range $15.00 – $40.00
Rating: Buy
Buy 88% · Hold 13% · Sell 0%

Get free alerts on ALMS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.